https://doi.org/10.1093/annonc/mdt494
M
Marija Balić
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
315
Papers
7.2K
Citations
39
h-index
87
i10-index
Marija Balić is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & Cancer Genomics and Diagnostics. The author has an h-index of 39, co-authored 268 publications.
ORCID: 0000-0001-9482-9191Papers by this author
worksPredicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
2013 · Annals of Oncology · 397 citations
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · The Lancet Oncology · 231 citations
https://doi.org/10.1016/s1470-2045(18)30862-3
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
2021 · Breast Cancer Research · 150 citations
https://doi.org/10.1186/s13058-021-01492-x
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
2013 · British Journal of Cancer · 58 citations
https://doi.org/10.1038/bjc.2013.367
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
2020 · European Journal of Cancer · 51 citations
https://doi.org/10.1016/j.ejca.2020.04.020
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
2017 · Clinical Cancer Research · 50 citations
https://doi.org/10.1158/1078-0432.ccr-16-2373
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat